[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"viral-pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:viral-pneumonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,87],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622691","investigation-of-the-effects-of-oxidized-antigens-on-the-t-cell-response-and-the-epigenetic-reprogramming-of-neutrophils-in-lung-diseases---oxigene---100622691",false,"NCT07386912","Investigation of the Effects of Oxidized Antigens on the T-Cell Response and the Epigenetic Reprogramming of Neutrophils in Lung Diseases - OXIGENE -","OXIGENE","Inclusion Criteria:\n\n* Diagnosis of an acute or chronic inflammatory lung disease, infectious or non-infectious, including asthma, COPD, pneumonia, tuberculosis, or viral pulmonary infection (e.g., COVID-19, influenza).\n* Age ≥ 18 years at the time of informed consent.\n* Ability to provide informed consent and consent to the collection and processing of clinical and laboratory data, as well as to the analysis of blood samples as part of study participation.\n* Sufficient physical condition to undergo a single venous blood draw (approximately 50 mL), as assessed by the treating physician.\n\nExclusion Criteria:\n\n* Active malignant disease or ongoing cancer therapy (e.g., chemotherapy or immunotherapy), due to potential immunological confounding.\n* Immunosuppressive therapy or known severe immunodeficiency that could interfere with the interpretation of cellular immune responses.\n* Pregnancy or breastfeeding, for general research-ethical reasons and to protect vulnerable populations.\n* Acute unstable clinical condition that, in the opinion of the treating physician, makes study participation unreasonable.\n* Known intolerance to blood sampling or relevant hematological disorders that could compromise the safety or feasibility of venipuncture.\n* Lack of capacity to provide informed consent or insufficient understanding of the study content despite supportive explanation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","The OXIGENE study is a research project that aims to better understand how the immune system behaves in people with lung diseases such as asthma, COPD, pneumonia, tuberculosis, and viral lung infections. By analyzing a single blood sample, the study examines how certain immune cells react during inflammation and infection, and whether lasting changes in these cells influence how strongly the body responds to disease. Although participants do not receive direct medical benefit, the results may help improve future diagnosis and treatment of lung diseases by providing deeper insight into immune responses.",[24,25,26,27,28],"Asthma","COPD","Bacterial Pneumonia","Viral Pneumonia","Tuberculosis",[30,31,32,33],"neutrophil granulocytes","epigenome","oxidation","antigens","NOT_YET_RECRUITING","2026-01-27",{"date":37,"type":38},"2026-02-04","ACTUAL",{"date":40,"type":20},"2026-02-01",{"date":42,"type":20},"2030-12",{"name":44,"class":45},"Research Center Borstel","OTHER",2,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100592912","phase-2-phase-2-study-of-inhaled-sng001-in-mechanically-ventilated-patients-with-respiratory-viral-infection-100592912","NCT06999603","Phase 2 Study of Inhaled SNG001 in Mechanically Ventilated Patients With Respiratory Viral Infection","A Phase 2, Two-part Study to Assess the Safety, Antiviral Biomarker Responses, and Efficacy of Inhaled SNG001 for the Treatment of Patients With a Confirmed Respiratory Virus Infection Undergoing Invasive Mechanical Ventilation","INVENT","Part 1 Inclusion Criteria:\n\nTo be eligible for randomisation into Part 1 of this study, each participant must fulfil the following criteria:\n\n1. Informed consent or legal representative's consent obtained.\n2. Patients ≥50 years of age at the time of consent.\n3. Patient admitted to the ICU and requiring invasive mechanical ventilation (IMV) due to a respiratory virus infection.\n4. Presence of Influenza A (Flu A), Influenza B (Flu B), respiratory syncytial virus (RSV), rhinovirus (RV), adenovirus, parainfluenza, human metapneumovirus (HMPV), or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a nose swab sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., reverse transcription polymerase chain reaction \\[RT-PCR\\]).\n5. Time from intubation to administration of first dose of study medication ≤48 hours.\n6. Women of childbearing potential must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \\\u003C55 years old.\n\nPart 1 Exclusion Criteria:\n\nA participant must not be randomised into Part 1 of the study if they meet any of the following criteria:\n\n1. Expected termination of IMV within 24 hours from the time of randomisation\n2. Life expectancy \\\u003C24 hours.\n3. Liver failure (Child-Pugh C).\n4. Severe congestive heart failure (New York Heart Association \\[NYHA\\] IV).\n5. Receipt of lung transplant.\n6. Known or suspected active tuberculosis, or infection with other mycobacteria\n7. Known or suspected active systemic fungal infection.\n8. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.\n9. Need for long-term mechanical ventilation prior to ICU admission.\n10. Use of inhaled sedation.\n11. Presence of tracheostomy or laryngectomy.\n12. Requirement for airway pressure release ventilation mode.\n13. History of hypersensitivity to natural or recombinant IFNβ or to any of the excipients in the drug preparation.\n14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.\n15. Participation in previous clinical studies of SNG001.\n16. Current or previous participation in another clinical study where the participant has received a dose of an Investigational Medicinal Product (IMP) containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.\n17. Known or suspected pregnancy.\n18. Females who are breast-feeding or lactating.\n19. Immunocompromising condition, including:\n\n    * Established acquired immune deficiency syndrome (AIDS) defined as a cluster of differentiation 4 (CD4) count \\\u003C200 cells\u002FmicroL, and\u002For the presence of any AIDS-defining condition;\n    * Haematological malignancy;\n    * Bone marrow transplantation; or\n    * Immunosuppressive therapy, including:\n    * Cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy), immune-cell depleting therapy, immunosuppressive therapy for autoimmune disorders, medications for prevention of organ transplantation rejection, administered within 6 months prior to randomisation; or\n    * Corticosteroids \\>20 mg of prednisone or equivalent per day administered continuously for \\>14 days prior to randomisation.\n20. Severe chronic lung disease requiring home oxygen therapy, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis.\n\nPart 2 Inclusion Criteria:\n\nTo be eligible for randomisation into Part 2 of this study, each participant must fulfil the following criteria:\n\n1.a Patients ≥18 and \\\u003C50 years of age at the time of consent, with an immunocompromising condition, including:\n\n* Solid tumour malignancy undergoing cancer therapy (e.g. chemo-, radio-, immuno-, hormone or other types of therapy);\n* Haematological malignancy in remission, with or without maintenance therapy;\n* Immunosuppressive therapy for autoimmune disease;\n* Therapy for prevention of organ transplant rejection;\n* Corticosteroids \\>20 mg of prednisone or equivalent per day, administered continuously for \\>14 days prior to randomisation or\n\n  1. b Patients ≥50 years of age at the time of consent, with or without an immunocompromising condition (as defined above).\n  2. Patient admitted to the ICU and requiring IMV due to a respiratory virus infection.\n  3. Presence of Flu A, Flu B, RSV, RV, adenovirus, parainfluenza, HMPV, or coronaviruses (including SARS-COV-2 and seasonal coronaviruses) in a Lower Respiratory Tract sample, confirmed by a positive virus test using a Sponsor approved rapid POC test (e.g., RT-PCR).\n  4. Time from intubation to administration of first dose of study medication ≤48 hours.\n  5. Informed consent or legal representative's consent obtained.\n  6. Women of childbearing potential must have a negative pregnancy test. For this study, women of childbearing potential are defined as women \\\u003C55 years old.\n\nPart 2 Exclusion Criteria:\n\nA participant must not be randomised into Part 2 of the study if they meet any of the following criteria:\n\n1. Expected termination of IMV within 24 hours from the time of randomisation.\n2. Life expectancy \\\u003C24 hours.\n3. Liver failure (Child-Pugh C).\n4. Severe congestive heart failure (NYHA IV).\n5. Receipt of lung transplant.\n6. Known or suspected active tuberculosis, or infection with other mycobacteria.\n7. Known or suspected systemic fungal infection.\n8. Immunocompromising condition, including:\n\n   * Haematological malignancy requiring induction or consolidation therapy within 3 months prior to randomisation;\n   * Bone marrow transplant within 6 months prior to randomisation;\n   * Solid organ transplant within 6 months prior to randomisation;\n   * Corticosteroids \\>75 mg of prednisone or equivalent per day, administered continuously for \\>7 days prior to randomisation;\n   * Methotrexate therapy at randomisation, if the indication is chemotherapy for cancer;\n   * Chimeric antigen receptor (CAR)-T cell therapy, administered within 3 months prior to randomisation;\n   * Ibrutinib or alemtuzumab, administered within 3 months prior to randomisation;\n   * Neutropenia \\\u003C500\u002Fmm3 not due to sepsis;\n   * Clinical presentation consistent with severe bone marrow suppression or pancytopenia;pancytopenia;\n   * Established AIDS, defined as a CD4 count \\\u003C200 cells\u002FmicroL, and\u002For the presence of any AIDS-defining condition.\n9. Anticipated transfer to another hospital which would prevent the participant from continuing in the study and completing protocol assessments.\n10. Need for long-term mechanical ventilation prior to ICU admission.\n11. Use of inhaled sedation.\n12. Presence of tracheostomy or laryngectomy\n13. History of hypersensitivity to natural or recombinant IFNβ or to any of the excipients in the drug preparation.\n14. Any condition, including findings in the patient's medical history or in the pre-randomisation study assessments that in the opinion of the Investigator, constitute a risk or a contraindication for participation in the study or that could interfere with the study objectives, conduct, or evaluation.\n15. Participation in previous clinical studies of SNG001.\n16. Current or previous participation in another clinical study where the participant has received a dose of an IMP containing small molecules within 30 days or 5 half-lives (whichever is longer) prior to entry into this study or containing biologicals within 3 months prior to entry into this study.\n17. Known or suspected pregnancy.\n18. Females who are breast-feeding or lactating.\n19. Severe chronic lung disease requiring home oxygen therapy, including chronic obstructive pulmonary disease, asthma, cystic fibrosis, or pulmonary fibrosis",{"count":56,"type":20},550,"INTERVENTIONAL",[59],"PHASE2","The goal of this Phase 2 study is to assess about the safety, antiviral biomarker responses and efficacy of SNG001 when given to patients requiring invasive mechanical ventilation due to a respiratory virus infection. Its ability to speed up virus clearance and reduce mortality, compared with standard of care, will be studied.\n\nThe study is split into two parts. All participants will receive standard of care in addition to SNG001 or placebo.\n\nIn Part 1, the safety of SNG001 will be assessed. Participants of 50 years and older will receive study drug or placebo once a day for up to 14 days, whilst in hospital.\n\nIn Part 2, the primary objective will be the efficacy of SNG001. Participants between 18 and 50 years with an immunocompromising condition and patients over 50 years (with or without an immunocompromising condition) will receive study drug once a day for up to 14 days, whilst in hospital.",[27],[63,64,65,66,67,68,69,70,71,72,73,74],"Influenza","Respiratory Syncytial Virus","Rhinovirus","Adenovirus","Human Metapneumovirus","Coronavirus","Intubated","Mechanically ventilated","Interferon","Intensive care","SARS-CoV-2","Parainfluenza","RECRUITING","2025-12-30",{"date":78,"type":38},"2025-12-31",{"date":80,"type":38},"2025-09-02",{"date":82,"type":20},"2027-05",{"name":84,"class":85},"Synairgen Research Ltd.","INDUSTRY",67,{"id":88,"slug":89,"hasResults":11,"nctId":90,"briefTitle":91,"officialTitle":91,"acronym":92,"eligibilityCriteria":93,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":94,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100571481","mucosal-associated-invariant-t-cell-during-viral-pneumonia-and-acute-respiratory-distress-syndrome-100571481","NCT06720818","Mucosal Associated Invariant T Cell During Viral Pneumonia and Acute Respiratory Distress Syndrome","MAIT-VECTORS","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients admitted to critical care (Intensive Care Unit, Continuous Monitoring Unit, Intensive Care Unit) at the CHRU de Tours\n* Patients admitted to critical care for one of the following reasons:\n\n  * Acute community-acquired pulmonary infection (pneumonia),\n  * Severe acute pancreatitis, with onset of ARDS criteria less than 48 hours ago,\n  * Severe isolated head injury requiring invasive mechanical ventilation,\n  * Severe burn defined by a burned surface area exceeding 20% and\u002For deep lesions exceeding 3% of the total body surface area, with the onset of ARDS criteria less than 48 hours ago,\n  * Patient admitted to Intensive Care Medicine, requiring invasive mechanical ventilation,\n  * Patient admitted to cardiac surgery for scheduled surgery for valve replacement and\u002For coronary artery bypass grafting, with inclusion the day before surgery,\n\nNon-inclusion criteria :\n\n* Patients with severe immunosuppression (impairing the ability to analyse the immune response, particularly T lymphocytes): active haematological malignancy, solid organ transplantation or bone marrow transplantation, systemic immunosuppressive treatment, ongoing chemotherapy (including immune checkpoint inhibitors).\n* Person who has objected to data processing\n* Patient under guardianship or curatorship",{"count":95,"type":20},150,"Viral pneumonia, including SARS-CoV-2 and influenza A virus (IAV), can culminate in acute respiratory distress syndrome (ARDS), a severe form of respiratory failure with high mortality. Uncontrolled local inflammatory response and impaired tissue repair are hallmarks of ARDS. However, lack of in-depth understanding of the immunopathology lead to limited identification of potential 'endotypes' who may benefit from individualized targeted therapies. Mucosal Associated Invariant T (MAIT) cells represent a peculiar lineage of T cells with a wide panel of effector functions. Thus, they emerge as potential key players and appealing targets in ARDS through their potent abilities to modulate immune response at barrier sites and promote tissue repair. Recent data from the investigators and others indicated that MAIT cells are highly activated in patients with Sars-Cov-2 and IAV ARDS, but the associated activation mechanisms and precise functions remain unknown.\n\nIn this context, the investigators aim at investigating the implication and potential harnessing of MAIT cells in severe viral pneumonias and associated ARDS by with a dedicated clinical study. First, the investigators will perform a comprehensive and longitudinal phenotyping of immune response during viral pneumonia-induced ARDS, including MAIT cells, in blood -and airway compartment for mechanically ventilated patients. To provide more insight into specificity of virally induced pneumonia and ARDS, longitudinal phenotyping of immune response of patients with bacterial pneumonia, and control patients with unrelated ARDS (severe trauma, pancreatitis or major surgery) will also be performed.",[27,98],"Acute Respiratory Distress Syndrome (ARDS)",[100,101,102],"Mucosal Associated Invariant T cell","physiopathology","immune response","2025-05-22",{"date":105,"type":38},"2025-05-29",{"date":107,"type":38},"2025-05-05",{"date":109,"type":20},"2029-02",{"name":111,"class":45},"University Hospital, Tours",1]